GlassScriptPhysician profile
Jasvir Kailey
NPI 1861946386
$6,218.71
in general payments reported to CMS, 2019-2025
31 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $430 · 2022: $1,440 · 2023: $1,096 · 2024: $1,890 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,348.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,374.54 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,001.35 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $480.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $379.19 | 2023-2025 | Caplyta |
| Pfizer INC. | $365.06 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.78 | 2022-2024 | Relistor |
| Novo Nordisk INC | $242.37 | 2021-2025 | Wegovy, Ozempic |
| Ardelyx, INC. | $214.71 | 2023-2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $213.71 | 2022-2025 | Invega Sustenna, Invega Trinza, Invega |
| Phathom Pharmaceuticals, INC. | $202.25 | 2024-2025 | Voquezna |
| Almatica Pharma LLC | $177.24 | 2022-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Amgen INC. | $137.30 | 2022-2023 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $128.57 | 2023-2025 | Zoryve, Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.82 | 2023-2025 | Jardiance |
| Ironwood Pharmaceuticals, INC | $104.90 | 2023-2024 | Linzess |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $100.95 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $93.37 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $84.16 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $75.58 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $62.43 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $50.87 | 2021 | |
| Collegium Pharmaceutical, INC. | $41.16 | 2021 | |
| Bausch Health US, LLC | $37.24 | 2021 | |
| Eisai INC. | $33.37 | 2021 | |
| Viiv Healthcare Company | $29.66 | 2024 | Apretude |
| Nestle Healthcare Nutrition INC. | $29.49 | 2021 | |
| Exact Sciences Corporation | $28.80 | 2023-2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $24.84 | 2021 | |
| Alkermes, INC. | $22.05 | 2023 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $19.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasvir Kailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.